Summary
The provided AI content is not a prescribing-information response about MOUNJARO’s thyroid C-cell tumor/MTC boxed warning; it discusses UK generic/patent availability and does not make verifiable label-based claims. Therefore, there is no measurable alignment to Sections 5.1/4/13.1/17.
Category Scores
Accurate Statements
Unsupported Statements
The response content focuses on UK patent/exclusivity timelines and generic availability for a “true generic of Mounjaro.”
The supplied FDA label excerpts provided in the prompt concern boxed warning topic Risk of Thyroid C-Cell Tumors, contraindications (MTC/MEN 2), nonclinical carcinogenicity (rats), and patient counseling (symptoms). The generic/patent-availability statements are not supported by, and are not responsive to, the supplied prescribing information content.
Contradictions
Important Omissions
Any label-anchored statement actually describing the FDA boxed warning content (e.g., that tirzepatide caused thyroid C-cell tumors in rats, that human relevance is unknown, contraindication in patients with personal/family history of MTC or MEN 2, and guidance on symptoms/monitoring).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Because the response does not provide the label-based thyroid C-cell tumor/MTC risk information it claims to evaluate, it could mislead users about the actual boxed-warning content and associated contraindication counseling requirements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Response content is about UK patent/generic availability rather than the FDA boxed warning topic Risk of Thyroid C-Cell Tumors/MTC described in Sections 5.1/4/13.1/17.
Suggested Improvement
Limit claims to what is stated in the FDA prescribing information for thyroid C-cell tumor/MTC risk: rodent finding and unknown human relevance (5.1/13.1), contraindication in patients with personal/family history of MTC or MEN 2 (4/5.1), patient counseling on symptoms (5.1 and 17), and monitoring language (uncertain value of routine calcitonin/ultrasound and evaluation steps if elevated).